nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—Prostate cancer—Riluzole—amyotrophic lateral sclerosis	0.0421	0.273	CcSEcCtD
Ruxolitinib—LTK—tongue—amyotrophic lateral sclerosis	0.00914	0.0248	CbGeAlD
Ruxolitinib—RPS6KA6—hindbrain—amyotrophic lateral sclerosis	0.00869	0.0236	CbGeAlD
Ruxolitinib—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.00853	0.0553	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00586	0.038	CcSEcCtD
Ruxolitinib—CAMK2G—nerve—amyotrophic lateral sclerosis	0.00556	0.0151	CbGeAlD
Ruxolitinib—MAP3K3—peripheral nervous system—amyotrophic lateral sclerosis	0.00552	0.015	CbGeAlD
Ruxolitinib—LRRK2—nerve—amyotrophic lateral sclerosis	0.00551	0.015	CbGeAlD
Ruxolitinib—RPS6KA6—embryo—amyotrophic lateral sclerosis	0.00543	0.0147	CbGeAlD
Ruxolitinib—PHKG2—hindbrain—amyotrophic lateral sclerosis	0.0054	0.0146	CbGeAlD
Ruxolitinib—HIPK2—hindbrain—amyotrophic lateral sclerosis	0.00519	0.0141	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00516	0.0335	CcSEcCtD
Ruxolitinib—RPS6KA6—brainstem—amyotrophic lateral sclerosis	0.00498	0.0135	CbGeAlD
Ruxolitinib—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00481	0.0312	CcSEcCtD
Ruxolitinib—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00473	0.0307	CcSEcCtD
Ruxolitinib—DYRK1A—hindbrain—amyotrophic lateral sclerosis	0.00467	0.0127	CbGeAlD
Ruxolitinib—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00461	0.0299	CcSEcCtD
Ruxolitinib—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00458	0.0297	CcSEcCtD
Ruxolitinib—PLK3—embryo—amyotrophic lateral sclerosis	0.00454	0.0123	CbGeAlD
Ruxolitinib—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00451	0.0292	CcSEcCtD
Ruxolitinib—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00451	0.0292	CcSEcCtD
Ruxolitinib—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00439	0.0284	CcSEcCtD
Ruxolitinib—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.0043	0.0279	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00427	0.0277	CcSEcCtD
Ruxolitinib—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00426	0.0276	CcSEcCtD
Ruxolitinib—CAMK2G—hindbrain—amyotrophic lateral sclerosis	0.00416	0.0113	CbGeAlD
Ruxolitinib—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00407	0.0264	CcSEcCtD
Ruxolitinib—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00405	0.0263	CcSEcCtD
Ruxolitinib—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00353	0.0229	CcSEcCtD
Ruxolitinib—ANKK1—nervous system—amyotrophic lateral sclerosis	0.00351	0.00952	CbGeAlD
Ruxolitinib—JAK1—embryo—amyotrophic lateral sclerosis	0.00348	0.00944	CbGeAlD
Ruxolitinib—DCLK1—embryo—amyotrophic lateral sclerosis	0.00348	0.00944	CbGeAlD
Ruxolitinib—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00347	0.0225	CcSEcCtD
Ruxolitinib—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00326	0.0211	CcSEcCtD
Ruxolitinib—PHKG2—brainstem—amyotrophic lateral sclerosis	0.00309	0.00839	CbGeAlD
Ruxolitinib—ROCK1—embryo—amyotrophic lateral sclerosis	0.003	0.00813	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00298	0.0193	CcSEcCtD
Ruxolitinib—HIPK2—brainstem—amyotrophic lateral sclerosis	0.00298	0.00808	CbGeAlD
Ruxolitinib—TAOK3—hindbrain—amyotrophic lateral sclerosis	0.00294	0.00798	CbGeAlD
Ruxolitinib—PRKG2—nervous system—amyotrophic lateral sclerosis	0.00291	0.00789	CbGeAlD
Ruxolitinib—Infection—Riluzole—amyotrophic lateral sclerosis	0.00286	0.0185	CcSEcCtD
Ruxolitinib—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00282	0.0183	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00282	0.0183	CcSEcCtD
Ruxolitinib—PRKG2—central nervous system—amyotrophic lateral sclerosis	0.0028	0.0076	CbGeAlD
Ruxolitinib—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.0028	0.0181	CcSEcCtD
Ruxolitinib—GRK1—nervous system—amyotrophic lateral sclerosis	0.00277	0.00753	CbGeAlD
Ruxolitinib—PRKCE—nervous system—amyotrophic lateral sclerosis	0.00272	0.00737	CbGeAlD
Ruxolitinib—CAMK1—medulla oblongata—amyotrophic lateral sclerosis	0.00271	0.00735	CbGeAlD
Ruxolitinib—DYRK1A—brainstem—amyotrophic lateral sclerosis	0.00268	0.00727	CbGeAlD
Ruxolitinib—GRK1—central nervous system—amyotrophic lateral sclerosis	0.00267	0.00725	CbGeAlD
Ruxolitinib—BMPR2—brainstem—amyotrophic lateral sclerosis	0.00267	0.00724	CbGeAlD
Ruxolitinib—PRKCE—central nervous system—amyotrophic lateral sclerosis	0.00261	0.00709	CbGeAlD
Ruxolitinib—PLK1—nervous system—amyotrophic lateral sclerosis	0.00261	0.00708	CbGeAlD
Ruxolitinib—RPS6KA6—nervous system—amyotrophic lateral sclerosis	0.00261	0.00708	CbGeAlD
Ruxolitinib—MAST1—nervous system—amyotrophic lateral sclerosis	0.00261	0.00708	CbGeAlD
Ruxolitinib—PRKCE—cerebellum—amyotrophic lateral sclerosis	0.00256	0.00693	CbGeAlD
Ruxolitinib—PLK1—central nervous system—amyotrophic lateral sclerosis	0.00251	0.00681	CbGeAlD
Ruxolitinib—RPS6KA6—central nervous system—amyotrophic lateral sclerosis	0.00251	0.00681	CbGeAlD
Ruxolitinib—MAST1—central nervous system—amyotrophic lateral sclerosis	0.00251	0.00681	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00248	0.0161	CcSEcCtD
Ruxolitinib—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00248	0.0161	CcSEcCtD
Ruxolitinib—DCLK3—nervous system—amyotrophic lateral sclerosis	0.00247	0.00671	CbGeAlD
Ruxolitinib—RPS6KA6—cerebellum—amyotrophic lateral sclerosis	0.00246	0.00666	CbGeAlD
Ruxolitinib—MAST1—cerebellum—amyotrophic lateral sclerosis	0.00246	0.00666	CbGeAlD
Ruxolitinib—CAMK1—spinal cord—amyotrophic lateral sclerosis	0.00242	0.00656	CbGeAlD
Ruxolitinib—CAMK2G—brainstem—amyotrophic lateral sclerosis	0.00239	0.00648	CbGeAlD
Ruxolitinib—DCLK3—central nervous system—amyotrophic lateral sclerosis	0.00238	0.00646	CbGeAlD
Ruxolitinib—LRRK2—brainstem—amyotrophic lateral sclerosis	0.00237	0.00642	CbGeAlD
Ruxolitinib—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00227	0.0147	CcSEcCtD
Ruxolitinib—JAK1—medulla oblongata—amyotrophic lateral sclerosis	0.00222	0.00603	CbGeAlD
Ruxolitinib—DCLK1—medulla oblongata—amyotrophic lateral sclerosis	0.00222	0.00603	CbGeAlD
Ruxolitinib—PRKG2—brain—amyotrophic lateral sclerosis	0.00222	0.00603	CbGeAlD
Ruxolitinib—RET—embryo—amyotrophic lateral sclerosis	0.00221	0.00601	CbGeAlD
Ruxolitinib—PLK3—nervous system—amyotrophic lateral sclerosis	0.00218	0.00591	CbGeAlD
Ruxolitinib—CAMK1D—medulla oblongata—amyotrophic lateral sclerosis	0.00217	0.00589	CbGeAlD
Ruxolitinib—PHKG2—medulla oblongata—amyotrophic lateral sclerosis	0.00216	0.00585	CbGeAlD
Ruxolitinib—DAPK2—medulla oblongata—amyotrophic lateral sclerosis	0.00212	0.00575	CbGeAlD
Ruxolitinib—GRK1—brain—amyotrophic lateral sclerosis	0.00212	0.00575	CbGeAlD
Ruxolitinib—PLK3—central nervous system—amyotrophic lateral sclerosis	0.0021	0.00569	CbGeAlD
Ruxolitinib—JAK2—embryo—amyotrophic lateral sclerosis	0.00209	0.00568	CbGeAlD
Ruxolitinib—PRKCE—brain—amyotrophic lateral sclerosis	0.00208	0.00563	CbGeAlD
Ruxolitinib—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00206	0.0134	CcSEcCtD
Ruxolitinib—CAMK1—nervous system—amyotrophic lateral sclerosis	0.00204	0.00553	CbGeAlD
Ruxolitinib—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00204	0.0132	CcSEcCtD
Ruxolitinib—DAPK3—medulla oblongata—amyotrophic lateral sclerosis	0.00199	0.00541	CbGeAlD
Ruxolitinib—RPS6KA6—brain—amyotrophic lateral sclerosis	0.00199	0.00541	CbGeAlD
Ruxolitinib—PLK1—brain—amyotrophic lateral sclerosis	0.00199	0.00541	CbGeAlD
Ruxolitinib—MAST1—brain—amyotrophic lateral sclerosis	0.00199	0.00541	CbGeAlD
Ruxolitinib—JAK1—spinal cord—amyotrophic lateral sclerosis	0.00198	0.00538	CbGeAlD
Ruxolitinib—DCLK1—spinal cord—amyotrophic lateral sclerosis	0.00198	0.00538	CbGeAlD
Ruxolitinib—MARK2—nervous system—amyotrophic lateral sclerosis	0.00198	0.00536	CbGeAlD
Ruxolitinib—CAMK1—central nervous system—amyotrophic lateral sclerosis	0.00196	0.00532	CbGeAlD
Ruxolitinib—CAMK1—cerebellum—amyotrophic lateral sclerosis	0.00192	0.0052	CbGeAlD
Ruxolitinib—MARK2—central nervous system—amyotrophic lateral sclerosis	0.0019	0.00516	CbGeAlD
Ruxolitinib—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.0019	0.0123	CcSEcCtD
Ruxolitinib—DAPK2—spinal cord—amyotrophic lateral sclerosis	0.00189	0.00513	CbGeAlD
Ruxolitinib—DCLK3—brain—amyotrophic lateral sclerosis	0.00189	0.00513	CbGeAlD
Ruxolitinib—MARK2—cerebellum—amyotrophic lateral sclerosis	0.00186	0.00505	CbGeAlD
Ruxolitinib—BMPR2—medulla oblongata—amyotrophic lateral sclerosis	0.00186	0.00505	CbGeAlD
Ruxolitinib—HIPK2—spinal cord—amyotrophic lateral sclerosis	0.00185	0.00502	CbGeAlD
Ruxolitinib—Headache—Riluzole—amyotrophic lateral sclerosis	0.0018	0.0117	CcSEcCtD
Ruxolitinib—DAPK3—spinal cord—amyotrophic lateral sclerosis	0.00178	0.00482	CbGeAlD
Ruxolitinib—TAOK2—cerebellum—amyotrophic lateral sclerosis	0.00172	0.00467	CbGeAlD
Ruxolitinib—TAOK3—brainstem—amyotrophic lateral sclerosis	0.00169	0.00457	CbGeAlD
Ruxolitinib—JAK3—nervous system—amyotrophic lateral sclerosis	0.00168	0.00456	CbGeAlD
Ruxolitinib—JAK1—nervous system—amyotrophic lateral sclerosis	0.00167	0.00453	CbGeAlD
Ruxolitinib—DCLK1—nervous system—amyotrophic lateral sclerosis	0.00167	0.00453	CbGeAlD
Ruxolitinib—CAMK2G—medulla oblongata—amyotrophic lateral sclerosis	0.00166	0.00452	CbGeAlD
Ruxolitinib—PLK3—brain—amyotrophic lateral sclerosis	0.00166	0.00452	CbGeAlD
Ruxolitinib—LRRK2—medulla oblongata—amyotrophic lateral sclerosis	0.00165	0.00448	CbGeAlD
Ruxolitinib—CAMK1D—nervous system—amyotrophic lateral sclerosis	0.00163	0.00442	CbGeAlD
Ruxolitinib—PHKG2—nervous system—amyotrophic lateral sclerosis	0.00162	0.0044	CbGeAlD
Ruxolitinib—JAK3—central nervous system—amyotrophic lateral sclerosis	0.00162	0.00439	CbGeAlD
Ruxolitinib—JAK1—central nervous system—amyotrophic lateral sclerosis	0.00161	0.00436	CbGeAlD
Ruxolitinib—DCLK1—central nervous system—amyotrophic lateral sclerosis	0.00161	0.00436	CbGeAlD
Ruxolitinib—LTK—brain—amyotrophic lateral sclerosis	0.00161	0.00436	CbGeAlD
Ruxolitinib—JAK3—cerebellum—amyotrophic lateral sclerosis	0.00158	0.00429	CbGeAlD
Ruxolitinib—JAK1—cerebellum—amyotrophic lateral sclerosis	0.00157	0.00427	CbGeAlD
Ruxolitinib—DCLK1—cerebellum—amyotrophic lateral sclerosis	0.00157	0.00427	CbGeAlD
Ruxolitinib—CAMK1D—central nervous system—amyotrophic lateral sclerosis	0.00157	0.00426	CbGeAlD
Ruxolitinib—STK16—nervous system—amyotrophic lateral sclerosis	0.00157	0.00425	CbGeAlD
Ruxolitinib—PHKG2—central nervous system—amyotrophic lateral sclerosis	0.00156	0.00423	CbGeAlD
Ruxolitinib—HIPK2—nervous system—amyotrophic lateral sclerosis	0.00156	0.00423	CbGeAlD
Ruxolitinib—CAMK1—brain—amyotrophic lateral sclerosis	0.00156	0.00422	CbGeAlD
Ruxolitinib—CAMK1D—cerebellum—amyotrophic lateral sclerosis	0.00153	0.00416	CbGeAlD
Ruxolitinib—MAP3K19—nervous system—amyotrophic lateral sclerosis	0.00153	0.00415	CbGeAlD
Ruxolitinib—PHKG2—cerebellum—amyotrophic lateral sclerosis	0.00153	0.00414	CbGeAlD
Ruxolitinib—MARK2—brain—amyotrophic lateral sclerosis	0.00151	0.0041	CbGeAlD
Ruxolitinib—STK16—central nervous system—amyotrophic lateral sclerosis	0.00151	0.0041	CbGeAlD
Ruxolitinib—HIPK2—central nervous system—amyotrophic lateral sclerosis	0.0015	0.00407	CbGeAlD
Ruxolitinib—DAPK2—cerebellum—amyotrophic lateral sclerosis	0.0015	0.00407	CbGeAlD
Ruxolitinib—DAPK3—nervous system—amyotrophic lateral sclerosis	0.0015	0.00407	CbGeAlD
Ruxolitinib—MAP3K7—medulla oblongata—amyotrophic lateral sclerosis	0.0015	0.00406	CbGeAlD
Ruxolitinib—CLK2—nervous system—amyotrophic lateral sclerosis	0.00148	0.00403	CbGeAlD
Ruxolitinib—BMP2K—spinal cord—amyotrophic lateral sclerosis	0.00148	0.00403	CbGeAlD
Ruxolitinib—CAMK2G—spinal cord—amyotrophic lateral sclerosis	0.00148	0.00403	CbGeAlD
Ruxolitinib—STK16—cerebellum—amyotrophic lateral sclerosis	0.00148	0.004	CbGeAlD
Ruxolitinib—MAP3K19—central nervous system—amyotrophic lateral sclerosis	0.00147	0.00399	CbGeAlD
Ruxolitinib—LRRK2—spinal cord—amyotrophic lateral sclerosis	0.00147	0.00399	CbGeAlD
Ruxolitinib—TYK2—medulla oblongata—amyotrophic lateral sclerosis	0.00147	0.00399	CbGeAlD
Ruxolitinib—HIPK2—cerebellum—amyotrophic lateral sclerosis	0.00147	0.00398	CbGeAlD
Ruxolitinib—MKNK2—medulla oblongata—amyotrophic lateral sclerosis	0.00145	0.00394	CbGeAlD
Ruxolitinib—DAPK3—central nervous system—amyotrophic lateral sclerosis	0.00144	0.00391	CbGeAlD
Ruxolitinib—ROCK1—nervous system—amyotrophic lateral sclerosis	0.00144	0.0039	CbGeAlD
Ruxolitinib—CLK2—central nervous system—amyotrophic lateral sclerosis	0.00143	0.00388	CbGeAlD
Ruxolitinib—RET—medulla oblongata—amyotrophic lateral sclerosis	0.00142	0.00384	CbGeAlD
Ruxolitinib—DAPK3—cerebellum—amyotrophic lateral sclerosis	0.00141	0.00383	CbGeAlD
Ruxolitinib—DYRK1A—nervous system—amyotrophic lateral sclerosis	0.0014	0.00381	CbGeAlD
Ruxolitinib—TAOK2—brain—amyotrophic lateral sclerosis	0.0014	0.00379	CbGeAlD
Ruxolitinib—BMPR2—nervous system—amyotrophic lateral sclerosis	0.0014	0.00379	CbGeAlD
Ruxolitinib—CLK2—cerebellum—amyotrophic lateral sclerosis	0.0014	0.00379	CbGeAlD
Ruxolitinib—ROCK1—central nervous system—amyotrophic lateral sclerosis	0.00139	0.00376	CbGeAlD
Ruxolitinib—DYRK1A—central nervous system—amyotrophic lateral sclerosis	0.00135	0.00366	CbGeAlD
Ruxolitinib—BMPR2—central nervous system—amyotrophic lateral sclerosis	0.00135	0.00365	CbGeAlD
Ruxolitinib—JAK2—medulla oblongata—amyotrophic lateral sclerosis	0.00134	0.00363	CbGeAlD
Ruxolitinib—MAP3K7—spinal cord—amyotrophic lateral sclerosis	0.00134	0.00362	CbGeAlD
Ruxolitinib—DYRK1A—cerebellum—amyotrophic lateral sclerosis	0.00132	0.00358	CbGeAlD
Ruxolitinib—BMPR2—cerebellum—amyotrophic lateral sclerosis	0.00132	0.00357	CbGeAlD
Ruxolitinib—TYK2—spinal cord—amyotrophic lateral sclerosis	0.00131	0.00356	CbGeAlD
Ruxolitinib—MKNK2—spinal cord—amyotrophic lateral sclerosis	0.00129	0.00351	CbGeAlD
Ruxolitinib—MAP3K3—medulla oblongata—amyotrophic lateral sclerosis	0.00129	0.0035	CbGeAlD
Ruxolitinib—JAK3—brain—amyotrophic lateral sclerosis	0.00128	0.00349	CbGeAlD
Ruxolitinib—JAK1—brain—amyotrophic lateral sclerosis	0.00128	0.00346	CbGeAlD
Ruxolitinib—DCLK1—brain—amyotrophic lateral sclerosis	0.00128	0.00346	CbGeAlD
Ruxolitinib—PLK4—brain—amyotrophic lateral sclerosis	0.00127	0.00344	CbGeAlD
Ruxolitinib—RET—spinal cord—amyotrophic lateral sclerosis	0.00126	0.00342	CbGeAlD
Ruxolitinib—NUAK2—cerebellum—amyotrophic lateral sclerosis	0.00126	0.00341	CbGeAlD
Ruxolitinib—CAMK2G—nervous system—amyotrophic lateral sclerosis	0.00125	0.00339	CbGeAlD
Ruxolitinib—BMP2K—nervous system—amyotrophic lateral sclerosis	0.00125	0.00339	CbGeAlD
Ruxolitinib—CAMK1D—brain—amyotrophic lateral sclerosis	0.00125	0.00338	CbGeAlD
Ruxolitinib—LRRK2—nervous system—amyotrophic lateral sclerosis	0.00124	0.00336	CbGeAlD
Ruxolitinib—PHKG2—brain—amyotrophic lateral sclerosis	0.00124	0.00336	CbGeAlD
Ruxolitinib—DAPK2—brain—amyotrophic lateral sclerosis	0.00122	0.0033	CbGeAlD
Ruxolitinib—CAMK2G—central nervous system—amyotrophic lateral sclerosis	0.0012	0.00327	CbGeAlD
Ruxolitinib—BMP2K—central nervous system—amyotrophic lateral sclerosis	0.0012	0.00327	CbGeAlD
Ruxolitinib—STK16—brain—amyotrophic lateral sclerosis	0.0012	0.00325	CbGeAlD
Ruxolitinib—LRRK2—central nervous system—amyotrophic lateral sclerosis	0.00119	0.00324	CbGeAlD
Ruxolitinib—JAK2—spinal cord—amyotrophic lateral sclerosis	0.00119	0.00324	CbGeAlD
Ruxolitinib—HIPK2—brain—amyotrophic lateral sclerosis	0.00119	0.00323	CbGeAlD
Ruxolitinib—CAMK2G—cerebellum—amyotrophic lateral sclerosis	0.00118	0.00319	CbGeAlD
Ruxolitinib—BMP2K—cerebellum—amyotrophic lateral sclerosis	0.00118	0.00319	CbGeAlD
Ruxolitinib—TAOK3—medulla oblongata—amyotrophic lateral sclerosis	0.00118	0.00319	CbGeAlD
Ruxolitinib—MAP3K19—brain—amyotrophic lateral sclerosis	0.00117	0.00317	CbGeAlD
Ruxolitinib—LRRK2—cerebellum—amyotrophic lateral sclerosis	0.00117	0.00316	CbGeAlD
Ruxolitinib—MAP3K3—spinal cord—amyotrophic lateral sclerosis	0.00115	0.00312	CbGeAlD
Ruxolitinib—DAPK3—brain—amyotrophic lateral sclerosis	0.00115	0.00311	CbGeAlD
Ruxolitinib—MAP3K2—nervous system—amyotrophic lateral sclerosis	0.00114	0.00308	CbGeAlD
Ruxolitinib—CLK2—brain—amyotrophic lateral sclerosis	0.00113	0.00308	CbGeAlD
Ruxolitinib—TYK2—nervous system—amyotrophic lateral sclerosis	0.0011	0.003	CbGeAlD
Ruxolitinib—ROCK1—brain—amyotrophic lateral sclerosis	0.0011	0.00298	CbGeAlD
Ruxolitinib—MAP3K2—central nervous system—amyotrophic lateral sclerosis	0.00109	0.00297	CbGeAlD
Ruxolitinib—MKNK2—nervous system—amyotrophic lateral sclerosis	0.00109	0.00296	CbGeAlD
Ruxolitinib—DYRK1A—brain—amyotrophic lateral sclerosis	0.00107	0.00291	CbGeAlD
Ruxolitinib—MAP3K2—cerebellum—amyotrophic lateral sclerosis	0.00107	0.0029	CbGeAlD
Ruxolitinib—BMPR2—brain—amyotrophic lateral sclerosis	0.00107	0.0029	CbGeAlD
Ruxolitinib—TYK2—central nervous system—amyotrophic lateral sclerosis	0.00106	0.00289	CbGeAlD
Ruxolitinib—RET—nervous system—amyotrophic lateral sclerosis	0.00106	0.00288	CbGeAlD
Ruxolitinib—MAP3K7—cerebellum—amyotrophic lateral sclerosis	0.00106	0.00287	CbGeAlD
Ruxolitinib—MKNK2—central nervous system—amyotrophic lateral sclerosis	0.00105	0.00285	CbGeAlD
Ruxolitinib—TAOK3—spinal cord—amyotrophic lateral sclerosis	0.00105	0.00284	CbGeAlD
Ruxolitinib—TYK2—cerebellum—amyotrophic lateral sclerosis	0.00104	0.00282	CbGeAlD
Ruxolitinib—MKNK2—cerebellum—amyotrophic lateral sclerosis	0.00103	0.00278	CbGeAlD
Ruxolitinib—IRAK1—cerebellum—amyotrophic lateral sclerosis	0.00103	0.00278	CbGeAlD
Ruxolitinib—RET—central nervous system—amyotrophic lateral sclerosis	0.00102	0.00278	CbGeAlD
Ruxolitinib—NUAK2—brain—amyotrophic lateral sclerosis	0.00102	0.00277	CbGeAlD
Ruxolitinib—JAK2—nervous system—amyotrophic lateral sclerosis	0.00101	0.00273	CbGeAlD
Ruxolitinib—RET—cerebellum—amyotrophic lateral sclerosis	0.001	0.00271	CbGeAlD
Ruxolitinib—MAP3K3—nervous system—amyotrophic lateral sclerosis	0.000969	0.00263	CbGeAlD
Ruxolitinib—JAK2—central nervous system—amyotrophic lateral sclerosis	0.000968	0.00263	CbGeAlD
Ruxolitinib—CAMK2G—brain—amyotrophic lateral sclerosis	0.000956	0.00259	CbGeAlD
Ruxolitinib—BMP2K—brain—amyotrophic lateral sclerosis	0.000956	0.00259	CbGeAlD
Ruxolitinib—LRRK2—brain—amyotrophic lateral sclerosis	0.000947	0.00257	CbGeAlD
Ruxolitinib—JAK2—cerebellum—amyotrophic lateral sclerosis	0.000946	0.00257	CbGeAlD
Ruxolitinib—MAP3K3—central nervous system—amyotrophic lateral sclerosis	0.000933	0.00253	CbGeAlD
Ruxolitinib—MAP3K3—cerebellum—amyotrophic lateral sclerosis	0.000912	0.00247	CbGeAlD
Ruxolitinib—TAOK3—nervous system—amyotrophic lateral sclerosis	0.000883	0.0024	CbGeAlD
Ruxolitinib—MAP3K2—brain—amyotrophic lateral sclerosis	0.000868	0.00235	CbGeAlD
Ruxolitinib—MAP3K7—brain—amyotrophic lateral sclerosis	0.00086	0.00233	CbGeAlD
Ruxolitinib—TAOK3—central nervous system—amyotrophic lateral sclerosis	0.00085	0.00231	CbGeAlD
Ruxolitinib—TYK2—brain—amyotrophic lateral sclerosis	0.000844	0.00229	CbGeAlD
Ruxolitinib—IRAK1—brain—amyotrophic lateral sclerosis	0.000833	0.00226	CbGeAlD
Ruxolitinib—MKNK2—brain—amyotrophic lateral sclerosis	0.000833	0.00226	CbGeAlD
Ruxolitinib—TAOK3—cerebellum—amyotrophic lateral sclerosis	0.000831	0.00225	CbGeAlD
Ruxolitinib—RET—brain—amyotrophic lateral sclerosis	0.000813	0.00221	CbGeAlD
Ruxolitinib—JAK2—brain—amyotrophic lateral sclerosis	0.000768	0.00208	CbGeAlD
Ruxolitinib—MAP3K3—brain—amyotrophic lateral sclerosis	0.00074	0.00201	CbGeAlD
Ruxolitinib—TAOK3—brain—amyotrophic lateral sclerosis	0.000675	0.00183	CbGeAlD
Ruxolitinib—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000268	0.000728	CbGeAlD
Ruxolitinib—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000258	0.000701	CbGeAlD
Ruxolitinib—BMPR2—Signaling Pathways—C3—amyotrophic lateral sclerosis	5.39e-05	0.000113	CbGpPWpGaD
Ruxolitinib—JAK1—Axon guidance—VEGFA—amyotrophic lateral sclerosis	5.38e-05	0.000113	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	5.33e-05	0.000112	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	5.33e-05	0.000112	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—CASP9—amyotrophic lateral sclerosis	5.31e-05	0.000111	CbGpPWpGaD
Ruxolitinib—ROCK1—Axon guidance—VEGFA—amyotrophic lateral sclerosis	5.29e-05	0.000111	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—SOD1—amyotrophic lateral sclerosis	5.29e-05	0.000111	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	5.25e-05	0.00011	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	5.21e-05	0.000109	CbGpPWpGaD
Ruxolitinib—PRKCE—Hemostasis—VEGFA—amyotrophic lateral sclerosis	5.19e-05	0.000109	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CST3—amyotrophic lateral sclerosis	5.18e-05	0.000109	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	5.17e-05	0.000108	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	5.17e-05	0.000108	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CD40LG—amyotrophic lateral sclerosis	5.17e-05	0.000108	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	5.17e-05	0.000108	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—C3—amyotrophic lateral sclerosis	5.13e-05	0.000108	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—CASP9—amyotrophic lateral sclerosis	5.1e-05	0.000107	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VCP—amyotrophic lateral sclerosis	5.06e-05	0.000106	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	5.04e-05	0.000106	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	5.02e-05	0.000105	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—C3—amyotrophic lateral sclerosis	5e-05	0.000105	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—C3—amyotrophic lateral sclerosis	4.98e-05	0.000104	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—C3—amyotrophic lateral sclerosis	4.96e-05	0.000104	CbGpPWpGaD
Ruxolitinib—MAP3K7—MAPK Signaling Pathway—TP53—amyotrophic lateral sclerosis	4.92e-05	0.000103	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	4.92e-05	0.000103	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—PTGS2—amyotrophic lateral sclerosis	4.91e-05	0.000103	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VCP—amyotrophic lateral sclerosis	4.9e-05	0.000103	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	4.9e-05	0.000103	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.88e-05	0.000102	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	4.87e-05	0.000102	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—C3—amyotrophic lateral sclerosis	4.84e-05	0.000102	CbGpPWpGaD
Ruxolitinib—PRKG2—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.84e-05	0.000101	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—C3—amyotrophic lateral sclerosis	4.83e-05	0.000101	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	4.79e-05	0.0001	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	4.75e-05	9.95e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	4.75e-05	9.95e-05	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	4.74e-05	9.93e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—ERBB4—amyotrophic lateral sclerosis	4.73e-05	9.92e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—SQSTM1—amyotrophic lateral sclerosis	4.71e-05	9.86e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	4.66e-05	9.77e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—APOE—amyotrophic lateral sclerosis	4.65e-05	9.75e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	4.65e-05	9.75e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—C3—amyotrophic lateral sclerosis	4.64e-05	9.73e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.59e-05	9.61e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—C3—amyotrophic lateral sclerosis	4.57e-05	9.58e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—SQSTM1—amyotrophic lateral sclerosis	4.57e-05	9.57e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Factors involved in megakaryocyte development and platelet production—TP53—amyotrophic lateral sclerosis	4.56e-05	9.55e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	4.54e-05	9.53e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	4.48e-05	9.39e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CD40LG—amyotrophic lateral sclerosis	4.45e-05	9.32e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—SQSTM1—amyotrophic lateral sclerosis	4.43e-05	9.29e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	4.43e-05	9.28e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—MMP9—amyotrophic lateral sclerosis	4.42e-05	9.27e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—ATF1—amyotrophic lateral sclerosis	4.41e-05	9.25e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—VEGFA—amyotrophic lateral sclerosis	4.38e-05	9.18e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—ERBB4—amyotrophic lateral sclerosis	4.37e-05	9.16e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	4.36e-05	9.14e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	4.35e-05	9.11e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	4.3e-05	9.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	4.3e-05	9.01e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	4.3e-05	9.01e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—ATF1—amyotrophic lateral sclerosis	4.28e-05	8.98e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—MMP9—amyotrophic lateral sclerosis	4.28e-05	8.96e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	4.23e-05	8.87e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	4.22e-05	8.84e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	4.21e-05	8.83e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—MMP9—amyotrophic lateral sclerosis	4.21e-05	8.82e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CASP9—amyotrophic lateral sclerosis	4.2e-05	8.81e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	4.17e-05	8.74e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—ATF1—amyotrophic lateral sclerosis	4.16e-05	8.71e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	4.15e-05	8.71e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.15e-05	8.69e-05	CbGpPWpGaD
Ruxolitinib—PHKG2—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.11e-05	8.62e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	4.09e-05	8.57e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CASP9—amyotrophic lateral sclerosis	4.08e-05	8.55e-05	CbGpPWpGaD
Ruxolitinib—PLK1—Cell Cycle—TP53—amyotrophic lateral sclerosis	4.06e-05	8.51e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	4.04e-05	8.47e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	4e-05	8.39e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—VEGFA—amyotrophic lateral sclerosis	3.97e-05	8.33e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	3.96e-05	8.3e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CASP9—amyotrophic lateral sclerosis	3.96e-05	8.3e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	3.94e-05	8.25e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—C3—amyotrophic lateral sclerosis	3.93e-05	8.24e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CST3—amyotrophic lateral sclerosis	3.93e-05	8.23e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Hemostasis—TP53—amyotrophic lateral sclerosis	3.92e-05	8.22e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	3.92e-05	8.22e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	3.84e-05	8.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VCP—amyotrophic lateral sclerosis	3.83e-05	8.03e-05	CbGpPWpGaD
Ruxolitinib—PLK4—Cell Cycle—TP53—amyotrophic lateral sclerosis	3.79e-05	7.94e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	3.78e-05	7.92e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—C3—amyotrophic lateral sclerosis	3.78e-05	7.91e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CASP9—amyotrophic lateral sclerosis	3.77e-05	7.9e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—VEGFA—amyotrophic lateral sclerosis	3.77e-05	7.9e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.76e-05	7.87e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	3.75e-05	7.86e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	3.71e-05	7.78e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	3.69e-05	7.74e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—ERBB4—amyotrophic lateral sclerosis	3.6e-05	7.54e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	3.59e-05	7.53e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.57e-05	7.49e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.56e-05	7.45e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.55e-05	7.44e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.53e-05	7.4e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.52e-05	7.37e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.5e-05	7.34e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—ERBB4—amyotrophic lateral sclerosis	3.49e-05	7.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—SQSTM1—amyotrophic lateral sclerosis	3.46e-05	7.26e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	3.46e-05	7.25e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	3.41e-05	7.15e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—ERBB4—amyotrophic lateral sclerosis	3.39e-05	7.1e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CD40LG—amyotrophic lateral sclerosis	3.38e-05	7.09e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—APOE—amyotrophic lateral sclerosis	3.38e-05	7.08e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—MMP9—amyotrophic lateral sclerosis	3.35e-05	7.03e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	3.34e-05	7.01e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.34e-05	6.99e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—TP53—amyotrophic lateral sclerosis	3.31e-05	6.93e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	3.29e-05	6.91e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CD40LG—amyotrophic lateral sclerosis	3.28e-05	6.88e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3.26e-05	6.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	3.26e-05	6.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ATF1—amyotrophic lateral sclerosis	3.25e-05	6.81e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—IGF1—amyotrophic lateral sclerosis	3.23e-05	6.76e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—ERBB4—amyotrophic lateral sclerosis	3.22e-05	6.76e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.19e-05	6.69e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—PTGS2—amyotrophic lateral sclerosis	3.19e-05	6.68e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.19e-05	6.68e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD40LG—amyotrophic lateral sclerosis	3.19e-05	6.68e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	3.18e-05	6.66e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—MMP9—amyotrophic lateral sclerosis	3.16e-05	6.62e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CASP9—amyotrophic lateral sclerosis	3.09e-05	6.48e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.06e-05	6.41e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	3.04e-05	6.38e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.02e-05	6.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—VEGFA—amyotrophic lateral sclerosis	3.01e-05	6.31e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.01e-05	6.31e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3e-05	6.28e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—C3—amyotrophic lateral sclerosis	2.99e-05	6.27e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.95e-05	6.19e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.95e-05	6.19e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—C3—amyotrophic lateral sclerosis	2.9e-05	6.08e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.88e-05	6.03e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.86e-05	6e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CASP9—amyotrophic lateral sclerosis	2.86e-05	5.98e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.85e-05	5.98e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—TP53—amyotrophic lateral sclerosis	2.85e-05	5.97e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2.84e-05	5.94e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.83e-05	5.93e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—C3—amyotrophic lateral sclerosis	2.81e-05	5.9e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.77e-05	5.81e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.75e-05	5.76e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	2.72e-05	5.71e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.72e-05	5.7e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.71e-05	5.68e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.69e-05	5.64e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.69e-05	5.63e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	2.65e-05	5.56e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	2.65e-05	5.56e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	2.65e-05	5.56e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ERBB4—amyotrophic lateral sclerosis	2.65e-05	5.55e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.64e-05	5.53e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.56e-05	5.36e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.54e-05	5.33e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.5e-05	5.24e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—APOE—amyotrophic lateral sclerosis	2.49e-05	5.23e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD40LG—amyotrophic lateral sclerosis	2.49e-05	5.22e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—ERBB4—amyotrophic lateral sclerosis	2.44e-05	5.12e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	2.43e-05	5.08e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.41e-05	5.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.41e-05	5.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—MMP9—amyotrophic lateral sclerosis	2.39e-05	5.01e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.37e-05	4.96e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.33e-05	4.88e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.33e-05	4.88e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PTGS2—amyotrophic lateral sclerosis	2.32e-05	4.85e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.27e-05	4.76e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.26e-05	4.74e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.26e-05	4.73e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.25e-05	4.73e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.24e-05	4.69e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—C3—amyotrophic lateral sclerosis	2.2e-05	4.61e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.19e-05	4.59e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.19e-05	4.58e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2.15e-05	4.5e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.12e-05	4.45e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	2.12e-05	4.44e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—VEGFA—amyotrophic lateral sclerosis	2.11e-05	4.42e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.1e-05	4.4e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.07e-05	4.34e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.06e-05	4.32e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.05e-05	4.29e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2e-05	4.19e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.96e-05	4.11e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.96e-05	4.1e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.93e-05	4.05e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.92e-05	4.03e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	1.92e-05	4.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—APOE—amyotrophic lateral sclerosis	1.89e-05	3.96e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.88e-05	3.93e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.82e-05	3.81e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.8e-05	3.77e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.76e-05	3.69e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.75e-05	3.67e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.75e-05	3.66e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.71e-05	3.59e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTGS2—amyotrophic lateral sclerosis	1.71e-05	3.58e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.69e-05	3.55e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.65e-05	3.47e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.61e-05	3.37e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—amyotrophic lateral sclerosis	1.59e-05	3.34e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.51e-05	3.15e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.49e-05	3.12e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.48e-05	3.11e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.48e-05	3.1e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	1.45e-05	3.05e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.44e-05	3.03e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.42e-05	2.98e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.42e-05	2.98e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.4e-05	2.93e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.4e-05	2.93e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	1.34e-05	2.81e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.33e-05	2.79e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.32e-05	2.77e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—amyotrophic lateral sclerosis	1.3e-05	2.72e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.28e-05	2.68e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.26e-05	2.63e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.14e-05	2.4e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.12e-05	2.35e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.11e-05	2.33e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	1.1e-05	2.31e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.09e-05	2.29e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.08e-05	2.27e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.08e-05	2.26e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.05e-05	2.2e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.02e-05	2.13e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.71e-06	2.04e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	9.65e-06	2.02e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	9.49e-06	1.99e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.43e-06	1.98e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.14e-06	1.92e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.42e-06	1.76e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	7.96e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	7.34e-06	1.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.15e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	7.12e-06	1.49e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.91e-06	1.45e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.92e-06	1.24e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.44e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.4e-06	1.13e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	4.47e-06	9.38e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.07e-06	6.43e-06	CbGpPWpGaD
